Direxion Daily S&P Biotech Bull 3X Shares (LABU)

NYSEARCA: LABU · IEX Real-Time Price · USD
136.51
+3.89 (2.93%)
Jul 12, 2024, 4:00 PM EDT - Market closed
2.93%
Assets $1.22B
Expense Ratio 0.96%
PE Ratio n/a
Shares Out 9.52M
Dividend (ttm) $0.52
Dividend Yield 0.38%
Ex-Dividend Date Jun 25, 2024
Payout Ratio n/a
1-Year Return +10.27%
Volume 2,384,981
Open 136.52
Previous Close 132.62
Day's Range 134.01 - 140.86
52-Week Low 48.40
52-Week High 176.99
Beta 3.51
Holdings 151
Inception Date May 28, 2015

About LABU

Fund Home Page

The Direxion Daily S&P Biotech Bull 3X Shares (LABU) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times exposure to the S&P Biotechnology Select Industry Index. LABU was launched on May 28, 2015 and is issued by Direxion.

Asset Class Equity
Category Trading--Leveraged Equity
Region North America
Stock Exchange NYSEARCA
Ticker Symbol LABU
ETF Provider Direxion
Index Tracked S&P Biotechnology Select Industry

Top 10 Holdings

272.16% of assets
Name Symbol Weight
S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP n/a 51.19%
S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP n/a 43.61%
S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP n/a 40.11%
S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP n/a 38.25%
S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP n/a 28.00%
S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP n/a 25.33%
DREYFUS GOVT CASH MAN INS n/a 17.58%
S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX SWAP n/a 13.19%
GOLDMAN FINL SQ TRSRY INST 506 n/a 9.08%
DREYFUS TRSRY SECURITIES CASH MGMT n/a 5.82%
View More Holdings

Dividends

Ex-Dividend Amount Pay Date
Jun 25, 2024 $0.15021 Jul 2, 2024
Mar 19, 2024 $0.16064 Mar 26, 2024
Dec 21, 2023 $0.20968 Dec 29, 2023
Sep 19, 2023 $0.0404 Sep 26, 2023
Jun 21, 2023 $0.1736 Jun 28, 2023
Dec 23, 2019 $0.1062 Dec 31, 2019
Full Dividend History

News

Taking On Volatility With Geared ETFs

Direxion's Dave Mazza is seeing many traders using inverse and leveraged ETFs in the recent market movement.

Other symbols: SOXL
2 years ago - ETFcom

A Biotech ETF For Aggressive, Risk-Tolerant Investors

The biotechnology sector has been on fire thanks to news from Biogen Inc. (NASDAQ: BIIB). The FDA approved its controverisal drug that can treat Alzheimer's Disease.

3 years ago - Benzinga

Heating Up: Three Leveraged ETFs For Summer Earnings

As the broad market knocks on the door of all-time highs in the midst of a still-raging public health crisis, traders have had to simultaneously ride the bullish wave (in most sectors) while also mode...

Other symbols: NAILRETL
4 years ago - Benzinga

With Biotech Scorching, Traders Show LABU Love

The coronavirus pandemic is fueling gains for biotechnology exchange traded funds this year and the leverage members of this group are participating in the fun.

4 years ago - Benzinga

3 Leveraged Healthcare ETFs Soaring This Month

The new coronavirus from China has claimed more than 800 lives and there are now more than 37,000 documented cases of the respiratory illness worldwide, making it more deadly than the 2003 SARS epidem...

Other symbols: CUREPILL
4 years ago - Benzinga

Where to Buy Booming Biotech ETFs

Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.

Other symbols: PBEXBI
5 years ago - Investopedia

Jablonski: Biotech presents a good buying opportunity

Sylvia Jablonski of Direxion discusses why biotech stocks and ETFs are attractive right now, due to their cheapness relative to the rest of the market.

Other symbols: CUREXLV
5 years ago - CNBC Television

These Are The Leveraged ETFs At Play When Trade War Worries Strike

The U.S.-China trade war is more than 18 months old. And in that time the conflict has taken a toll on stocks across the world and put company executives and market watchers alike on edge.

Other symbols: SOXLSOXSLABDTECLTECS
5 years ago - Benzinga

Biotech stocks fall after Trump promises executive order drug prices

CNBC's Meg Tirrell reports on the dip in biotech stocks after President Donald Trump promised that an executive order on drug prices is coming.

5 years ago - CNBC Television

A Beloved Biotech ETF Could Lure Traders Again

With biotechnology stocks and the related exchange-traded funds recently showing some signs of life, it could be just a matter of time before aggressive traders embraced leveraged healthcare ETFs.

5 years ago - Benzinga

It's Time To Consider Leveraged Healthcare ETFs

For traders using leveraged sector exchange-traded funds, one key to successfully using these products in the short-term fashion in which they are intended is to treat leveraged ETFs as event-driven t...

Other symbols: CURE
5 years ago - Benzinga

Big Moves In Leveraged Biotech ETFs

Leveraged biotechnology exchange traded funds (ETFs) are known to make big moves, but sometimes those moves are not always about price action.

5 years ago - Benzinga